Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

SAN MATEO, Calif., April 11, 2023 /PRNewswire/ — Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibodies today announced that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs…